Conventional Dendritic Cells and Slan


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 26 03 2020
accepted: 22 06 2020
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 14 4 2021
Statut: epublish

Résumé

HIV-2 infection is characterized by low viremia and slow disease progression as compared to HIV-1 infection. Circulating CD14

Identifiants

pubmed: 32903610
doi: 10.3389/fimmu.2020.01658
pmc: PMC7438582
doi:

Substances chimiques

Biomarkers 0
SECISBP2L protein, human 0
Tumor Suppressor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1658

Informations de copyright

Copyright © 2020 Iannetta, Isnard, Manuzak, Guillerme, Notin, Bailly, Andrieu, Amraoui, Vimeux, Figueiredo, Charmeteau-de Muylder, Vaton, Hatton, Samri, Autran, Thiébaut, Chaghil, Glohi, Charpentier, Descamps, Brun-Vézinet, Matheron, Cheynier and Hosmalin.

Références

Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Curr Opin HIV AIDS. 2014 Sep;9(5):478-84
pubmed: 25093528
J Clin Invest. 2019 Dec 2;129(12):5474-5488
pubmed: 31710311
J Exp Med. 2010 Jun 7;207(6):1247-60
pubmed: 20479116
Immunity. 2002 Sep;17(3):289-301
pubmed: 12354382
J Allergy Clin Immunol. 2011 Mar;127(3):787-94.e1-9
pubmed: 21377044
J Infect Dis. 2013 Jun 1;207(11):1730-42
pubmed: 23460749
Curr Opin HIV AIDS. 2016 Sep;11(5):537-544
pubmed: 27254747
PLoS One. 2014 May 12;9(5):e97171
pubmed: 24819230
Cancer Res. 2018 Jul 1;78(13):3544-3559
pubmed: 29748373
Lancet HIV. 2018 Nov 1;:
pubmed: 30392769
Blood. 2015 Dec 10;126(24):2601-10
pubmed: 26443621
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
J Infect Dis. 2011 Oct 15;204(8):1227-36
pubmed: 21917896
Immunol Lett. 2013 Apr;152(1):32-41
pubmed: 23557598
Immunobiology. 2019 Mar;224(2):231-241
pubmed: 30522891
J Immunol. 2003 May 15;170(10):5089-94
pubmed: 12734354
J Infect Dis. 2016 Oct 1;214 Suppl 2:S58-66
pubmed: 27625432
J Exp Med. 2010 Jun 7;207(6):1273-81
pubmed: 20479115
J Infect Dis. 2018 Sep 8;218(8):1291-1295
pubmed: 29800140
Rev Med Virol. 2013 Jul;23(4):221-40
pubmed: 23444290
J Exp Med. 2010 Jun 7;207(6):1261-71
pubmed: 20479117
J Clin Invest. 2014 Jul;124(7):3147-58
pubmed: 24911151
AIDS. 2001 Sep 7;15(13):1657-63
pubmed: 11546940
Curr HIV Res. 2016;14(4):331-9
pubmed: 26785889
PLoS One. 2008 Jun 25;3(6):e2516
pubmed: 18575590
Eur J Immunol. 1995 Dec;25(12):3418-24
pubmed: 8566032
Lancet. 1987 Jan 17;1(8525):128-32
pubmed: 2879971
AIDS. 1999 May 7;13(7):759-66
pubmed: 10357374
Mucosal Immunol. 2018 Jan;11(1):236-248
pubmed: 28513595
AIDS. 2013 Jun 1;27(9):1387-95
pubmed: 23435298
Immunity. 2010 Sep 24;33(3):375-86
pubmed: 20832340
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Eur J Immunol. 2000 Jul;30(7):1872-83
pubmed: 10940876
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
J Infect Dis. 2019 Sep 26;220(9):1414-1419
pubmed: 31323092
Clin Infect Dis. 2012 Nov 15;55(10):1417-25
pubmed: 22911639
J Exp Med. 2010 Jun 7;207(6):1283-92
pubmed: 20479118
J Virol. 2006 Mar;80(5):2529-38
pubmed: 16474159
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):254-8
pubmed: 26825178
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
J Virol. 2011 Mar;85(5):2429-38
pubmed: 21159859
J Virus Erad. 2017 Jan 1;3(1):24-33
pubmed: 28275455
AIDS. 2011 Mar 27;25(6):865-7
pubmed: 21358376
J Infect Dis. 2004 Nov 15;190(10):1889-92
pubmed: 15499547
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):E89; author reply E90
pubmed: 19706497
Microbiol Immunol. 1993;37(10):785-92
pubmed: 7904721
Blood. 2012 Sep 13;120(11):2259-68
pubmed: 22802339
J Infect Dis. 2011 Jul 1;204(1):154-63
pubmed: 21628670
Microb Pathog. 2017 Oct;111:331-337
pubmed: 28801271
Blood. 2001 Nov 15;98(10):3016-21
pubmed: 11698285
AIDS. 2010 Mar 27;24(6):819-31
pubmed: 20224308
AIDS Care. 2016 Nov;28(11):1434-40
pubmed: 27242060
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6718-23
pubmed: 19357303
J Immunol. 2007 May 15;178(10):6581-9
pubmed: 17475889

Auteurs

Marco Iannetta (M)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Stéphane Isnard (S)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Jennifer Manuzak (J)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Jean-Baptiste Guillerme (JB)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Mathilde Notin (M)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Karine Bailly (K)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Muriel Andrieu (M)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Sonia Amraoui (S)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Lene Vimeux (L)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Suzanne Figueiredo (S)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Bénédicte Charmeteau-de Muylder (B)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Laura Vaton (L)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Etienne X Hatton (EX)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Assia Samri (A)

Sorbonne Université, Inserm 1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France.

Brigitte Autran (B)

Sorbonne Université, Inserm 1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France.

Rodolphe Thiébaut (R)

INSERM, Univ. Bordeaux, CIC 1401, UMR 1219, Bordeaux Population Health Research Center, CHU Bordeaux, Bordeaux, France.

Nathalie Chaghil (N)

INSERM, Univ. Bordeaux, CIC 1401, UMR 1219, Bordeaux Population Health Research Center, CHU Bordeaux, Bordeaux, France.

David Glohi (D)

Service des Maladies Infectieuses, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.

Charlotte Charpentier (C)

Service des Maladies Infectieuses, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.

Diane Descamps (D)

Service des Maladies Infectieuses, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.

Françoise Brun-Vézinet (F)

Service des Maladies Infectieuses, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.

Sophie Matheron (S)

Service des Maladies Infectieuses, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.
INSERM, UMR 1137, IAME (Infection Antimicrobials Modelling Evolution), Université de Paris, Paris, France.

Remi Cheynier (R)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Anne Hosmalin (A)

Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH